Cellular immunogenicity and immunotoxicity assays help scientists design, validate, and translate therapeutic research into treatments that weaponize the immune response against cancer.

Biologic-based therapeutics are known to generate anti-drug immune responses or immunogenicity in clinical patients which can lead to altered pharmacokinetics, decreased drug efficacy, and unwanted ...

Robust and comparable immunogenicity was observed between adolescents and young adults who received 2- or 3-dose schedules of ...

At PEPperPRINT, we developed a novel pipeline to enable: Profiling potential T-cell immunogenicity through chip-based MHC-associated peptide proteomics (MAPPs) assay Discrimination of regulatory T ...

Serum samples for anti-panitumumab antibody testing were collected from mCRC patients enrolled in 4 panitumumab clinical trials (20050184, 20060277, 20050181, and 20050203). Patients in these ...

The industry uses singleplex assays to detect and characterize ADA responses in a tiered sequential manner. This presentation will introduce the concepts of Immunogenicity and share a novel ...

In the vaccine efficacy and preclinical safety space, this includes immunogenicity assays, neurovirulence testing, antibody-dependent enhancement and vaccine-associated enhanced disease models and ...

Comparing the immunogenicity of currently used TNF-α ... making it difficult or impossible for a drug-sensitive assay to detect anti-etanercept antibodies. One approach to overcome this problem ...

It is possible to substantially enhance these antibodies’ therapeutic potential via humanization, effectively reducing ...

PROVIDENCE, R.I., Dec. 7, 2024 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by ...

Immunogenicity bioanalysis follows an industry-standard tiered-testing approach, including assay screening (all samples), ...